[{"address1": "42127 Pleasant Forest Court", "city": "Ashburn", "state": "VA", "zip": "20148-7349", "country": "United States", "phone": "703 980 4182", "website": "https://quoinpharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.", "fullTimeEmployees": 4, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael  Myers Ph.D.", "age": 61, "title": "Co-Founder, CEO & Chairman", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 661800, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Denise  Carter", "age": 54, "title": "Co-Founder, COO & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 537800, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gordon Bruce Dunn J.D.", "age": 59, "title": "Chief Financial Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 394200, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.7519, "open": 0.75, "dayLow": 0.7129, "dayHigh": 0.79, "regularMarketPreviousClose": 0.7519, "regularMarketOpen": 0.75, "regularMarketDayLow": 0.7129, "regularMarketDayHigh": 0.79, "beta": 2.029, "forwardPE": -0.6280165, "volume": 486181, "regularMarketVolume": 486181, "averageVolume": 2549648, "averageVolume10days": 13243740, "averageDailyVolume10Day": 13243740, "marketCap": 3024379, "fiftyTwoWeekLow": 0.477, "fiftyTwoWeekHigh": 6.18, "fiftyDayAverage": 0.60316, "twoHundredDayAverage": 1.213705, "currency": "USD", "enterpriseValue": -6322477, "floatShares": 3856392, "sharesOutstanding": 3979970, "sharesShort": 15195, "sharesShortPriorMonth": 12316, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.0038, "heldPercentInsiders": 0.02387, "heldPercentInstitutions": 0.077309996, "shortRatio": 0.01, "shortPercentOfFloat": 0.0038, "bookValue": 1.879, "priceToBook": 0.40441725, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -8277870, "trailingEps": -5.05, "forwardEps": -1.21, "enterpriseToEbitda": 0.715, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "QNRX", "underlyingSymbol": "QNRX", "shortName": "Quoin Pharmaceuticals, Ltd.", "longName": "Quoin Pharmaceuticals, Ltd.", "firstTradeDateEpochUtc": 1470058200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "32cb2815-c927-3d74-8136-d444e5765139", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.7599, "targetHighPrice": 10.0, "targetLowPrice": 2.0, "targetMeanPrice": 4.67, "targetMedianPrice": 2.0, "recommendationMean": 2.3, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 12570589, "totalCashPerShare": 3.158, "ebitda": -8836608, "totalDebt": 3223733, "quickRatio": 3.18, "currentRatio": 3.345, "debtToEquity": 43.108, "returnOnAssets": -0.36318, "returnOnEquity": -1.00033, "freeCashflow": -5049371, "operatingCashflow": -7986664, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-24"}]